WO2011083999A3 - 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 - Google Patents
바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 Download PDFInfo
- Publication number
- WO2011083999A3 WO2011083999A3 PCT/KR2011/000098 KR2011000098W WO2011083999A3 WO 2011083999 A3 WO2011083999 A3 WO 2011083999A3 KR 2011000098 W KR2011000098 W KR 2011000098W WO 2011083999 A3 WO2011083999 A3 WO 2011083999A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biguanide derivative
- preparation
- pharmaceutical composition
- active ingredient
- composition containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/02—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of guanidine from cyanamide, calcium cyanamide or dicyandiamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/04—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of guanidine from ammonium thiocyanate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/06—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11731937A EP2522654A2 (en) | 2010-01-06 | 2011-01-06 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient |
US13/520,905 US9133110B2 (en) | 2010-01-06 | 2011-01-06 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient |
CN201180005604.XA CN102725264B (zh) | 2010-01-06 | 2011-01-06 | 双胍衍生物、其制备方法以及包含其作为活性成分的药物组合物 |
US14/847,692 US9464042B2 (en) | 2010-01-06 | 2015-09-08 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0001021 | 2010-01-06 | ||
KR20100001021 | 2010-01-06 | ||
KR1020110001442A KR101285719B1 (ko) | 2010-01-06 | 2011-01-06 | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
KR10-2011-0001442 | 2011-01-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/520,905 A-371-Of-International US9133110B2 (en) | 2010-01-06 | 2011-01-06 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient |
US14/847,692 Division US9464042B2 (en) | 2010-01-06 | 2015-09-08 | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011083999A2 WO2011083999A2 (ko) | 2011-07-14 |
WO2011083999A3 true WO2011083999A3 (ko) | 2011-11-17 |
Family
ID=44919837
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/000098 WO2011083999A2 (ko) | 2010-01-06 | 2011-01-06 | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
PCT/KR2011/000097 WO2011083998A2 (ko) | 2010-01-06 | 2011-01-06 | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/000097 WO2011083998A2 (ko) | 2010-01-06 | 2011-01-06 | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
Country Status (6)
Country | Link |
---|---|
US (5) | US9416098B2 (ko) |
EP (2) | EP2522654A2 (ko) |
JP (1) | JP2013516461A (ko) |
KR (4) | KR101274981B1 (ko) |
CN (2) | CN102725263A (ko) |
WO (2) | WO2011083999A2 (ko) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102725263A (zh) | 2010-01-06 | 2012-10-10 | 韩诺生物制药株式会社 | 双胍衍生物、其制备方法以及包含所述双胍衍生物作为活性成分的药物组合物 |
EP2742020B1 (en) * | 2011-08-08 | 2017-10-25 | Immunomet Therapeutics Inc. | N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
CN103827083B (zh) * | 2011-08-08 | 2016-03-09 | 伊谬诺米特医疗有限公司 | N1-环胺-n5-取代苯基双胍衍生物及其制备方法和含有该衍生物的药物组合物 |
WO2013188452A1 (en) * | 2012-06-11 | 2013-12-19 | The Regents Of The University Of California | Compounds and methods of treating cancer |
AU2013292519B2 (en) | 2012-07-19 | 2017-12-07 | Drexel University | Sigma receptor ligands for modulating cellular protein homeostasis |
WO2014123364A1 (en) * | 2013-02-07 | 2014-08-14 | Hanall Biopharma Co., Ltd. | N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
KR102034899B1 (ko) * | 2013-02-07 | 2019-10-22 | 이뮤노메트테라퓨틱스 인코포레이티드 | Ν1-고리아민-ν5-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
WO2015026215A1 (ko) * | 2013-08-23 | 2015-02-26 | 가톨릭대학교 산학협력단 | 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물 |
KR101642587B1 (ko) | 2013-08-23 | 2016-07-25 | 가톨릭대학교 산학협력단 | 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물 |
US10272055B2 (en) * | 2014-03-06 | 2019-04-30 | Regents Of The University Of Minnesota | Therapeutic compounds and methods |
WO2015160220A1 (en) * | 2014-04-17 | 2015-10-22 | Hanall Biopharma Co., Ltd. | Guanidine compounds and use thereof |
US20160120876A1 (en) * | 2014-04-28 | 2016-05-05 | Chi-Ying Huang | Pharmaceutical composition for treatment of cancer using phenothiazine |
JP6462002B2 (ja) * | 2014-04-29 | 2019-01-30 | ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション | 免疫疾患治療効果を有する新規化合物およびその使用 |
WO2015167243A1 (ko) * | 2014-04-29 | 2015-11-05 | 가톨릭대학교 산학협력단 | 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도 |
CN104262205B (zh) * | 2014-09-02 | 2017-04-12 | 浙江工业大学 | N‑芳基双胍氢碘酸盐类化合物及其制备方法和应用 |
CN104230760B (zh) * | 2014-09-02 | 2016-07-06 | 浙江工业大学 | N-芳基取代的双胍氢溴酸盐类化合物及制备方法和应用 |
KR102216701B1 (ko) * | 2014-11-20 | 2021-02-18 | 이뮤노메트테라퓨틱스 인코포레이티드 | 바이구아나이드 화합물 및 이의 용도 |
CZ307146B6 (cs) * | 2015-03-31 | 2018-02-07 | Kkcg Se | Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva |
US10215554B2 (en) * | 2015-04-17 | 2019-02-26 | Industry-University Cooperation Foundation Hanyang University | Apparatus and method for non-contact sample analyzing using terahertz wave |
US10590081B2 (en) | 2015-04-30 | 2020-03-17 | Immunomet Therapeutics Inc. | Guanidine compounds and use thereof |
CN104961656B (zh) * | 2015-05-27 | 2017-01-25 | 山西大学 | 一种双胍化合物及其制备方法 |
CN104829497B (zh) * | 2015-06-01 | 2017-07-18 | 上海仁力医药科技有限公司 | 一种双胍类化合物及其制备方法和应用 |
CN104829496B (zh) * | 2015-06-01 | 2017-03-15 | 高尔医药科技(上海)有限公司 | 双胍类化合物及其制备方法与应用 |
CN104926695B (zh) * | 2015-06-01 | 2017-05-31 | 上海仁力医药科技有限公司 | 防治辐射损伤的化合物rl‑66301、单晶及其制备方法和应用 |
KR101949451B1 (ko) | 2015-10-13 | 2019-05-10 | 주식회사 이노파마스크린 | 염증성 장 질환 및 아토피 피부염 치료용 조성물 |
KR101796479B1 (ko) | 2016-06-24 | 2017-11-13 | 주식회사 인코스팜 | 피부 염증 또는 노화를 개선하는 신규 자가포식작용 활성화 유도 화합물 |
US11168068B2 (en) | 2016-07-18 | 2021-11-09 | Janssen Pharmaceutica Nv | Tau PET imaging ligands |
WO2018106907A1 (en) * | 2016-12-08 | 2018-06-14 | Novatarg, Inc. | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary |
CN106986791A (zh) * | 2017-05-11 | 2017-07-28 | 杜剑平 | 一种***的药物化合物及其制备方法和应用 |
US11117870B2 (en) | 2017-11-01 | 2021-09-14 | Drexel University | Compounds, compositions, and methods for treating diseases |
CN108030777B (zh) * | 2017-12-05 | 2019-11-12 | 湖南师范大学 | 氯胍在制备抗肿瘤药物中的应用 |
JP7358403B2 (ja) | 2018-06-05 | 2023-10-10 | アンスティテュ・クリー | ビグアニジルラジカルを含む新規化合物及びその使用 |
CN108785106B (zh) * | 2018-06-05 | 2021-03-16 | 中国科学院上海硅酸盐研究所 | 一种胶状含银磷酸钙纳米复合材料及其制备方法和应用 |
CN111018748A (zh) * | 2019-12-27 | 2020-04-17 | 广东省生物医药技术研究所 | 化合物(s)-1-(1-萘基)乙基双胍及其制备方法和应用 |
US11091426B1 (en) | 2020-05-05 | 2021-08-17 | United Arab Emirates University | Cycloheptylamine derivatives as anti-diabetic agents |
WO2022106505A1 (en) | 2020-11-18 | 2022-05-27 | Institut Curie | Dimers of biguanidines and their therapeutic uses |
US20240067603A1 (en) * | 2020-12-16 | 2024-02-29 | Regents Of The University Of Minnesota | Cubanyl biguanide compounds |
CN113354561B (zh) * | 2021-04-17 | 2023-03-28 | 中山大学 | 双胍衍生物及其应用与制剂 |
CN114605291B (zh) * | 2022-04-10 | 2023-11-14 | 烟台大学 | 蒽甲基-双胍类抗癌化合物及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
WO2001091696A2 (fr) * | 2000-05-26 | 2001-12-06 | Centre National De La Recherche Scientifique (Cnrs) | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
WO2009113092A2 (en) * | 2008-01-23 | 2009-09-17 | Usv Limited | Process for preparation of proguanil hydrochloride |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB607720A (en) * | 1945-12-31 | 1948-09-03 | Arthur Donald Ainley | Manufacture of biguanide derivatives |
DE833959C (de) * | 1946-01-25 | 1952-03-13 | Ici Ltd | Verfahren zur Herstellung von chemotherapeutisch wertvollen Biguanidderivaten |
US2531404A (en) * | 1948-02-25 | 1950-11-28 | Ici Ltd | Biguanide compounds |
US2631146A (en) * | 1952-11-13 | 1953-03-10 | American Cyanamid Co | Biguanide salts of penicillin |
US2768204A (en) * | 1956-02-27 | 1956-10-23 | American Cyanamid Co | Guanylchloroformamidine hydrochlorides |
DE1291331B (de) * | 1964-10-16 | 1969-03-27 | Sueddeutsche Kalkstickstoff | Verfahren zur Herstellung von Biguanidsalzen aus Guanidinen |
US3366650A (en) * | 1965-10-07 | 1968-01-30 | Squibb & Sons Inc | Tetra-and penta-fluoro-phenyl- and phenylalkyl-biguanides and salts thereof |
JPS5283906A (en) * | 1976-01-01 | 1977-07-13 | Hoffmann La Roche | Biguanide salt |
US4183958A (en) * | 1978-09-26 | 1980-01-15 | Gaf Corporation | Fungicidal 1-(alkoxyphenyl)-5-(substituted phenyl) biguanide compounds |
CA2064664C (en) * | 1991-04-05 | 2000-01-11 | Hiroshi Ishikawa | Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives |
JP2662343B2 (ja) * | 1991-06-19 | 1997-10-08 | 大塚製薬株式会社 | モノビグアナイド誘導体とこの誘導体を含有した消毒薬 |
JP4694841B2 (ja) * | 2002-09-20 | 2011-06-08 | アンドルックス ラボズ リミテッド ライアビリティ カンパニー | ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤 |
KR100774774B1 (ko) * | 2006-07-20 | 2007-11-07 | 일동제약주식회사 | 메트포르민 서방성 제제 및 그 제조방법 |
CN105152983A (zh) * | 2007-01-29 | 2015-12-16 | 韩诺生物制药株式会社 | N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物 |
KR20090005513A (ko) * | 2007-07-09 | 2009-01-14 | 한올제약주식회사 | 메트포르민 말론산염, 그의 제조 방법 및 그를 포함하는약제학적 조성물 |
US8835506B2 (en) * | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
KR101041428B1 (ko) * | 2008-10-13 | 2011-06-14 | 한국화학연구원 | N1-2-티오펜-2-일에틸-n2-치환된 바이구아나이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
KR101083300B1 (ko) * | 2008-10-13 | 2011-11-14 | 한국화학연구원 | N1-벤조[1,3]다이옥솔-5-일메틸-n2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
CN102725263A (zh) | 2010-01-06 | 2012-10-10 | 韩诺生物制药株式会社 | 双胍衍生物、其制备方法以及包含所述双胍衍生物作为活性成分的药物组合物 |
-
2011
- 2011-01-06 CN CN2011800056035A patent/CN102725263A/zh active Pending
- 2011-01-06 KR KR1020110001438A patent/KR101274981B1/ko active IP Right Grant
- 2011-01-06 WO PCT/KR2011/000098 patent/WO2011083999A2/ko active Application Filing
- 2011-01-06 CN CN201180005604.XA patent/CN102725264B/zh active Active
- 2011-01-06 EP EP11731937A patent/EP2522654A2/en not_active Withdrawn
- 2011-01-06 KR KR1020110001442A patent/KR101285719B1/ko active IP Right Grant
- 2011-01-06 JP JP2012547967A patent/JP2013516461A/ja active Pending
- 2011-01-06 US US13/520,902 patent/US9416098B2/en active Active
- 2011-01-06 WO PCT/KR2011/000097 patent/WO2011083998A2/ko active Application Filing
- 2011-01-06 US US13/520,905 patent/US9133110B2/en active Active
- 2011-01-06 EP EP11731936.8A patent/EP2522653A4/en not_active Withdrawn
-
2013
- 2013-05-21 KR KR1020130057296A patent/KR101704683B1/ko active IP Right Grant
- 2013-06-04 KR KR1020130064239A patent/KR101715984B1/ko active IP Right Grant
-
2015
- 2015-09-08 US US14/847,692 patent/US9464042B2/en active Active
-
2016
- 2016-07-11 US US15/206,780 patent/US9993446B2/en active Active
-
2018
- 2018-05-10 US US15/976,613 patent/US10376480B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
WO2001091696A2 (fr) * | 2000-05-26 | 2001-12-06 | Centre National De La Recherche Scientifique (Cnrs) | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
WO2009113092A2 (en) * | 2008-01-23 | 2009-09-17 | Usv Limited | Process for preparation of proguanil hydrochloride |
Non-Patent Citations (1)
Title |
---|
CARRINGTON, H. C. ET AL.: "Synthetic Antimalarials. Part XLIX. The structure and Synthesis of the Dihydrotriazine Metabolite of Proguanil", J. CHEM. SOC., 1 January 1954 (1954-01-01), pages 1017 - 1031 * |
Also Published As
Publication number | Publication date |
---|---|
KR101274981B1 (ko) | 2013-06-18 |
KR101715984B1 (ko) | 2017-03-14 |
KR20130060250A (ko) | 2013-06-07 |
US9133110B2 (en) | 2015-09-15 |
US20150376123A1 (en) | 2015-12-31 |
KR20110081095A (ko) | 2011-07-13 |
WO2011083998A2 (ko) | 2011-07-14 |
KR20130069704A (ko) | 2013-06-26 |
CN102725264B (zh) | 2014-12-17 |
US9416098B2 (en) | 2016-08-16 |
US20120309799A1 (en) | 2012-12-06 |
JP2013516461A (ja) | 2013-05-13 |
EP2522653A2 (en) | 2012-11-14 |
EP2522653A4 (en) | 2013-06-12 |
US20160317478A1 (en) | 2016-11-03 |
US9464042B2 (en) | 2016-10-11 |
US20120283299A1 (en) | 2012-11-08 |
US20180256520A1 (en) | 2018-09-13 |
CN102725263A (zh) | 2012-10-10 |
US9993446B2 (en) | 2018-06-12 |
WO2011083998A3 (ko) | 2011-10-27 |
KR20110081093A (ko) | 2011-07-13 |
CN102725264A (zh) | 2012-10-10 |
KR101704683B1 (ko) | 2017-02-09 |
EP2522654A2 (en) | 2012-11-14 |
WO2011083999A2 (ko) | 2011-07-14 |
US10376480B2 (en) | 2019-08-13 |
KR101285719B1 (ko) | 2013-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011083999A3 (ko) | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 | |
EP4071149A3 (en) | Heterocyclic compounds and uses thereof | |
WO2009111700A3 (en) | Oxadiazoanthracene compounds for the treatment of diabetes | |
WO2009149139A8 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
WO2007060140A3 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
MX2009012285A (es) | Inhibidores de diacilglicerol aciltransferasa. | |
WO2007107470A3 (en) | Pyrazoles as 11-beta-hsd-1 | |
WO2013022278A3 (en) | N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | |
EP2532388A3 (en) | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | |
WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
WO2008142859A1 (ja) | 新規なスピロオキシインドール化合物及びこれを含有する医薬 | |
WO2007056771A3 (en) | Compounds for the treatment of metabolic disorders | |
MX357780B (es) | Derivados policíclicos, proceso para su preparación y su uso farmacéutico. | |
WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
WO2009121939A3 (en) | C-aryl glycoside compounds for the treatment of diabetes and obesity | |
WO2008119685A3 (en) | Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators | |
WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
WO2011085643A8 (zh) | 吡啶并环衍生物 | |
WO2011123536A8 (en) | Polycyclic tetracycline compounds | |
WO2008079610A3 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
WO2013022279A3 (en) | N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | |
MY163762A (en) | Therapeutic agent for chronic renal failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180005604.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11731937 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012547968 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13520905 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1903/MUMNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011731937 Country of ref document: EP |